Full Text of PDF (361k)
Article in Japanese
Abstract
Case Report
A case of hepatitis B virus reactivation during treatment with osimertinib
Meiko Morita Yoshiyuki Oyama Shogo Nakamura Rie Mori Masaki Ikeda Hideki Kusagaya
Department of Respiratory Medicine, Shizuoka Saiseikai General Hospital
ABSTRACT
A 79-year-old woman was diagnosed with advanced lung adenocarcinoma harboring an epidermal growth factor receptor (EGFR) exon 19 deletion. At the same time, she was diagnosed as an inactive hepatitis B virus (HBV) carrier. After consultation with a gastroenterologist, we initiated osimertinib treatment without antiviral prophylaxis. After 8 months, she developed general malaise and was admitted to our hospital because of liver dysfunction. Her hepatitis B surface antigen and HBV-DNA levels were higher than those before treatment; therefore, she was diagnosed with HBV reactivation. Her condition improved with entecavir. HBV reactivation caused by EGFR-tyrosine kinase inhibitor is rare; however, a cautious clinical follow-up is necessary.
KEYWORDS
Lung cancer Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) Osimertinib Hepatitis B virus (HBV) reactivation
Received 25 Mar 2021 ／ Accepted 14 Jun 2021
AJRS, 10(5): 388-392, 2021
Copyright © The Japanese Respiratory Society All Rights Reserved.